Mayport LLC Acquires Shares of 49,681 Relay Therapeutics, Inc. $RLAY

Mayport LLC bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 49,681 shares of the company’s stock, valued at approximately $259,000.

Several other large investors also recently modified their holdings of the business. Quadrant Capital Group LLC raised its position in Relay Therapeutics by 245.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock valued at $41,000 after purchasing an additional 8,374 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Relay Therapeutics in the 2nd quarter worth approximately $47,000. Captrust Financial Advisors bought a new stake in shares of Relay Therapeutics in the 2nd quarter worth approximately $49,000. Cerity Partners LLC purchased a new position in shares of Relay Therapeutics during the second quarter valued at approximately $51,000. Finally, Jump Financial LLC purchased a new position in shares of Relay Therapeutics during the second quarter valued at approximately $53,000. 96.98% of the stock is owned by institutional investors.

Relay Therapeutics Stock Up 1.3%

RLAY opened at $10.26 on Wednesday. Relay Therapeutics, Inc. has a 52 week low of $1.77 and a 52 week high of $11.49. The stock has a market cap of $1.83 billion, a PE ratio of -6.33 and a beta of 1.55. The business has a 50 day moving average of $8.80 and a 200-day moving average of $7.33.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. The firm had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $4.34 million. Equities analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Insider Buying and Selling at Relay Therapeutics

In related news, CFO Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the completion of the transaction, the chief financial officer directly owned 250,996 shares of the company’s stock, valued at $1,912,589.52. This trade represents a 5.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Sanjiv Patel sold 43,168 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $7.82, for a total transaction of $337,573.76. Following the sale, the chief executive officer directly owned 661,041 shares in the company, valued at $5,169,340.62. The trade was a 6.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 93,302 shares of company stock worth $724,355. Corporate insiders own 4.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Oppenheimer reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research note on Monday. Guggenheim boosted their price objective on shares of Relay Therapeutics from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Citizens Jmp upped their price objective on shares of Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a report on Tuesday. Wells Fargo & Company raised their target price on shares of Relay Therapeutics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.17.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.